Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

An Acidic Milieu Created In Myeloma-Osteoclast Interaction Enhances Tumor Growth, but Triggers Anti-Myeloma Activity of Reveromycin A, a Novel Anti-Resorptive Agent

Keiichiro Watanabe, DDS, Masahiro Abe, MD, PhD, Qu Cui, MD, Makoto Kawatani, PhD, Masahiro Hiasa, DDS, PhD, Ayako Nakano, MD, PhD, Tadashi Jinno, MD, Takeshi Harada, MD, Shiro Fujii, MD, Shingen Nakamura, MD, Hirokazu Miki, MD, Kumiko Kagawa, MD, Kyoko Takeuchi, MD, PhD, Shuji Ozaki, MD, PhD, Eiji Tanaka, DDS, PhD, Hiroyuki Osada, PhD, Toshio Matsumoto, MD, PhD

Blood (2010) 116 (21): 454.

https://doi.org/10.1182/blood.V116.21.454.454

Published: 2010

Journal Articles

Hypoxia-Adapted CML Cells Are More Primitive Population and Are Eradicated by Glyoxalase-1 Inhibitors.

Miki Takeuchi, MD, Shinya Kimura, MD, PhD, Junya Kuroda, MD, PhD, Eishi Ashihara, MD, PhD, Makoto Kawatani, PhD, Hiroyuki Osada, PhD, Kazuo Umezawa, PhD, Eiko Yasui, PhD, Masaya Imoto, PhD, Takashi Tsuruo, MD, PhD, Asumi Yokota, MMSc, Ruriko Tanaka, MMSc, Rina Nagao, Tatsutoshi Nakahata, M.D., Ph.D., Yoshihide Fujiyama, MD, PhD, Taira Maekawa, MD, PhD

Blood (2009) 114 (22): 2166.

https://doi.org/10.1182/blood.V114.22.2166.2166

Published: 2009

Journal Articles

Roles of Osteoclasts in Leukemic Cells

Asumi Yokota, MMSc, Shinya Kimura, MD, PhD, Ruriko Tanaka, MMSc, Rina Nagao, Kazuki Sakai, MD, Hisayuki Yao, MD, Miki Takeuchi, MD, Makoto Kawatani, PhD, Hiroyuki Osada, PhD, Eishi Ashihara, MD, PhD, Taira Maekawa, MD, PhD

Blood (2008) 112 (11): 3184.

https://doi.org/10.1182/blood.V112.11.3184.3184

Published: 2008

Journal Articles

Glyoxalase-I Inhibition Eliminates Hypoxia-Adapted CML Cells Resistant to Imatinib, Dasatinib, and INNO-406

Miki Takeuchi, MD, Shinya Kimura, MD, PhD, Junya Kuroda, MD, PhD, Takashi Ushiki, MD, Makoto Kawatani, PhD, Hiroyuki Osada, PhD, Kazuo Umezawa, PhD, Eiko Yasui, PhD, Masaya Imoto, PhD, Takashi Tsuruo, MD, PhD, Keiko Hodohara, MD, PhD, Tatsutoshi Nakahata, MD, PhD, Yoshihide Fujiyama, MD, PhD, Taira Maekawa, MD, PhD

Blood (2008) 112 (11): 3185.

https://doi.org/10.1182/blood.V112.11.3185.3185

Published: 2008

Journal Articles

Glyoxalase-I Is a Potential Therapeutic Target for Chronic Myelogenous Leukemia Cells That Have Acquired Drug Resistance through Adaptation to Hypoxia.

Miki Takeuchi, Junya Kuroda, Shinya Kimura, Eishi Ashihara, Kazuo Umezawa, Eiko Yasui, Makoto Kawatani, Hiroyuki Osada, Keiko Hodohara, Yoshihide Fujiyama, Taira Maekawa

Blood (2007) 110 (11): 2931.

https://doi.org/10.1182/blood.V110.11.2931.2931

Published: 2007

NARROW

An Acidic Milieu Created In Myeloma-Osteoclast Interaction Enhances Tumor Growth, but Triggers Anti-Myeloma Activity of Reveromycin A, a Novel Anti-Resorptive Agent

Hypoxia-Adapted CML Cells Are More Primitive Population and Are Eradicated by Glyoxalase-1 Inhibitors.

Roles of Osteoclasts in Leukemic Cells

Glyoxalase-I Inhibition Eliminates Hypoxia-Adapted CML Cells Resistant to Imatinib, Dasatinib, and INNO-406

Glyoxalase-I Is a Potential Therapeutic Target for Chronic Myelogenous Leukemia Cells That Have Acquired Drug Resistance through Adaptation to Hypoxia.

Email alerts

ASH Publications

American Society of Hematology

An Acidic Milieu Created In Myeloma-Osteoclast Interaction Enhances Tumor Growth, but Triggers Anti-Myeloma Activity of Reveromycin A, a Novel Anti-Resorptive Agent

Hypoxia-Adapted CML Cells Are More Primitive Population and Are Eradicated by Glyoxalase-1 Inhibitors.

Roles of Osteoclasts in Leukemic Cells

Glyoxalase-I Inhibition Eliminates Hypoxia-Adapted CML Cells Resistant to Imatinib, Dasatinib, and INNO-406

Glyoxalase-I Is a Potential Therapeutic Target for Chronic Myelogenous Leukemia Cells That Have Acquired Drug Resistance through Adaptation to Hypoxia.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only